Southampton-led team to develop next-gen cancer treatments
Date:
A consortium led by the University of Southampton has received funding to develop next-generation treatments for cancer and chronic inflammation.
The consortium, made up of 10 academic research groups, four companies, a hospital and a non-profit organisation, has received £3.8 million from the Horizon Europe Marie Skłodowska-Curie Actions (MSCA) programme.
The funding will be used to advance cutting-edge treatments for lung cancer, blood cancers, and chronic inflammation using Oligonucleotides (ONs).
Read the full article here.
